Table 4 Relative risk (95%CI) for contralateral breast cancer according to treatment of first breast cancer among 5-year breast cancer survivors in the SEER cohort.
Outcome | |||||
|---|---|---|---|---|---|
Population | Treatment | All Contralateral Breast Cases | |||
Observed | RRa | 95%CI | P-valueb | ||
All first breast cancer | Radiotherapy | ||||
No/Unknownc | 4599 | 1 | |||
Yes | 5871 | 1.07 | 1.03–1.12 | <0.001 | |
Hormone therapy | |||||
No/Unknownc | 6596 | 1 | |||
Yes | 3874 | 0.92 | 0.88–0.96 | <0.001 | |
ER+ first breast cancer | Hormone therapy | ||||
No/Unknownc | 3511 | 1 | |||
Yes | 3421 | 0.95 | 0.90–0.99 | 0.039 | |
Radiotherapy with HT | |||||
No/Unknownc | 1021 | 1 | |||
Yes | 2400 | 1.03d | 0.95–1.11 | 0.489 | |
Radiotherapy without HT | |||||
No/Unknownc | 1784 | 1 | |||
Yes | 1727 | 1.09d | 1.02–1.17 | 0.010 | |
ER+ Contralateral Breast Cases | |||||
All first breast cancer | Radiotherapy | ||||
No/Unknownc | 3245 | 1 | |||
Yes | 4345 | 1.07 | 1.02–1.12 | 0.006 | |
Hormone therapy | |||||
No/Unknownc | 4618 | 1 | |||
Yes | 2972 | 0.96 | 0.91–1.01 | 0.090 | |
ER+ first breast cancer | Hormone therapy | ||||
No/Unknownc | 2714 | 1 | |||
Yes | 2679 | 0.94 | 0.89-0.99 | 0.035 | |
Radiotherapy with HT | |||||
No/Unknownc | 785 | 1 | |||
Yes | 1894 | 1.03e | 0.94–1.12 | 0.414 | |
Radiotherapy without HT | |||||
No/Unknownc | 1348 | ||||
Yes | 1366 | 1.12e | 1.04–1.21 | 0.004 | |
ER- Contralateral Breast Cases | |||||
All first breast cancer | Radiotherapy | ||||
No/Unknownc | 799 | 1 | |||
Yes | 1039 | 1.12 | 1.01–1.23 | 0.028 | |
Hormone therapy | |||||
No/Unknownc | 1248 | 1 | |||
Yes | 590 | 0.84 | 0.76–0.93 | <0.001 | |
ER+ first breast cancer | Hormone therapy | ||||
No/Unknownc | 401 | 1 | |||
Yes | 481 | 1.15 | 0.99–1.32 | 0.054 | |
Radiotherapy with HT | |||||
No/Unknownc | 141 | 1 | |||
Yes | 340 | 1.01 f | 0.83–1.24 | 0.69 | |
Radiotherapy without HT | |||||
No/Unknownc | 203 | 1 | |||
Yes | 198 | 1.10 f | 0.89–1.34 | 0.379 | |